Abstract:A facile hydrothermal strategy is employed to construct a core‐shell heterostructure sonosensitizer comprising metalloporphyrin (Fe‐TCPP) metal organic frameworks (MOFs) and bright DSNPs (NaErF4:Yb@NaLuF4). The coordination of Fe3+ into the macrocycle of TCPP at the MOFs shell is confirmed resulting in a marked decrease in TCPP phosphorescence and a significant increase in singlet oxygen generation, and the subsequent reduction of Fe3+ by GSH facilitates the restoration of DSNPs at 1525 nm, thereby significantly augmenting the generation of reactive oxygen species and enabling real‐time monitoring of sonodynamic therapy. Noninvasive sonodynamic therapy (SDT) shows promise for brain glioma treatment due to deep tissue‐penetrating capabilities (>10 cm) of ultrasound and high spatial resolutions. Yet, this technique is hindered by inefficient production of reactive oxygen species (ROS), resulting from the hypoxic tumor microenvironment (TME), high level of ROS scavenger glutathione (GSH), and the inability to visualize glioma in vivo for precise treatment management and monitoring in current sonosentizers. To address these challenges, we fabricated a core‐shell heterostructure sonosensitizer (labeled as DFM), in which meso‐tetra (4‐carboxyphenyl) porphine (TCPP) porphyrin metal‐organic frameworks (MOF, PCN‐224(Fe)) serve as a porous shell to contain approved chemotherapeutics sorafenib (SRF) to effectively inhibit GSH synthesis, while NaErF4:Yb@NaLuF4 nanoparticles as the core provide TME‐responsive NIR IIb (≈1500–1800 nm) luminescence at 1525 for precise optical imaging. Coordination of Fe3+ into the macrocycle of TCPP at the MOFs shell is found to, besides triggering ferroptosis, reduce TCPP phosphorescence (23% decrease) and increase the triplet state (T1) oxygen quenching, substantially promoting the singlet oxygen generation (2.6‐fold increase). Furthermore, GSH in TME facilitates the reduction of Fe3+ to Fe2+, thereby eliminating the luminescence quenching of Fe3+ and augmenting the NIR IIb luminescence of Er3+ (5‐fold increase) for nanoagents accumulation imaging in intracranial glioma, realizing dynamical monitoring of SDT processes. Compared to control groups, in vitro and in vivo experiments confirm the effective ROS generation and results in a 6‐fold volume reduction of brain gliomas, reaching a survival rate of 80% at 30 days posttreatment.

D‐type neuropeptide decorated AIEgen/RENP hybrid nanoprobes with light‐driven ROS generation ability for NIR‐II fluorescence imaging‐guided through‐skull photodynamic therapy of gliomas

Biomimetic Multifunctional Persistent Luminescence Nanoprobes for Long-Term Near-Infrared Imaging and Therapy of Cerebral and Cerebellar Gliomas

A Near-Infrared Triggered Multi-Functional Indocyanine Green Nanocomposite with NO Gas Release Function Inducing Improved Photothermal Therapy

Porphyrin-Based Organic Nanoparticles with NIR-IIa Fluorescence for Orthotopic Glioblastoma Theranostics

Dual-Site Förster Resonance Energy Transfer Route of Upconversion Nanoparticles-Based Brain-Targeted Nanotheranostic Boosts the Near-Infrared Phototherapy of Glioma.

X-ray Activated Nanoprodrug for Visualization of Cortical Microvascular Alterations and NIR-II Image-Guided Chemo-Radiotherapy of Glioblastoma

A D‐Y Shaped Neuropeptide Y Mimetic Peptide‐Dye Self‐Assembly with Maximal Emission Beyond 1300 nm and Glioma Mitochondrial Activity Modulation

Engineering NIR-IIb fluorescence of Er-based lanthanide nanoparticles for through-skull targeted imaging and imaging-guided surgery of orthotopic glioma

Brain Tumor Cell Membrane‐Coated Lanthanide‐Doped Nanoparticles for NIR‐IIb Luminescence Imaging and Surgical Navigation of Glioma

Miniature NIR‐II Nanoprobes for Active‐Targeted Phototheranostics of Brain Tumors

Metalloporphyrin MOFs‐Based Nanoagent Enabling Tumor Microenvironment Responsive Sonodynamic Therapy of Intracranial Glioma Signaled by NIR‐IIb Luminescence Imaging

Near Infrared-Activatable Biomimetic Nanoplatform for Tumor-Specific Drug Release, Penetration and Chemo-Photothermal Synergistic Therapy of Orthotopic Glioblastoma

Light-activatable and hyperthermia-sensitive “all-in-one” theranostics: NIR-II fluorescence imaging and chemo-photothermal therapy of subcutaneous glioblastoma by temperature-sensitive liposome-containing AIEgens and paclitaxel

Bright Aggregation-Induced-Emission Dots for Targeted Synergetic NIR-II Fluorescence and NIR-I Photoacoustic Imaging of Orthotopic Brain Tumors

An Activatable Phototheranostic Nanoplatform for Tumor Specific NIR-II Fluorescence Imaging and Synergistic NIR-II Photothermal-Chemodynamic Therapy.

Neutrophil‐Targeting Semiconducting Polymer Nanotheranostics for NIR‐II Fluorescence Imaging‐Guided Photothermal‐NO‐Immunotherapy of Orthotopic Glioblastoma

Novel YOF-Based Theranostic Agents with a Cascade Effect for NIR-II Fluorescence Imaging and Synergistic Starvation/Photodynamic Therapy of Orthotopic Gliomas.

Reversible pH-switchable NIR-II nano-photosensitizer for precise imaging and photodynamic therapy of tumors

Retro-enantio isomer of angiopep-2 assists nanoprobes across the blood-brain barrier for targeted magnetic resonance/fluorescence imaging of glioblastoma

Effective Phototheranostics of Brain Tumor Assisted by Near-Infrared-II Light-Responsive Semiconducting Polymer Nanoparticles

Targeted and Imaging-Guided in Vivo Photodynamic Therapy for Tumors Using Dual-Function, Aggregation-Induced Emission Nanoparticles